First Subject Dosed in Lipigon’s Phase I Clinical Study with Antisense Oligonucleotide Candidate Derived from Secarna Pharmaceutical’s LNAplus(TM) Technology Platform

31 May 2022
www.biospace.com
First in ClassOligonucleotideCollaborate
First antisense oligonucleotide (ASO) derived from Secarna's LNAplus™ technology platform to enter the clinic after a series of successful pre-clinical proof-of-concept programs in various indications LipigonLipigon received approval from the Swedish Medical Products Agency to commence a phase I clinical study with LNAplus™ ASO lead candidate, Lipisense, targeting ANGPTL4 for the treatment of severe hypertriglyceridemia as well as the rare disease Familial Chylomicronemia Syndrome (FCS): first subject dosed Development progress triggered undisclosed milestone payment to Secarna MUNICH and MARTINSRIED, GERMANY / ACCESSWIRE / May 31, 2022 / Secarna Pharmaceuticals GmbH & Co. KG ("Secarna"), a biopharmaceutical company focusing on the discovery and development of next-generation antisense oligonucleotide (ASO) therapies to address challenging or previously undruggable targets, is pleased to announce that the Company's partner Lipigon Pharmaceuticals AB ("LipigonLipigon") has advanced their lead candidate, Lipisense , into a phase 1 clinical study . Lipisense is an antisense oligonucleotide (ASO) discovered and developed with Secarna's proprietary LNAplus™ platform for the treatment of rare lipid-related-diseases. The Swedish Medical Products Agency approved the trial last week and the first subject has already been dosed. Progression of the drug candidate into the clinic triggered an undisclosed milestone payment to Secarna. "We congratulate our partner Lipigon on advancing their lead candidate into the clinic," said Alexander Gebauer, M.D. Ph.D., CEO of Secarna Pharmaceuticals . "This is a major milestone for Secarna as well because Lipisense is the first ASO derived from our LNAplus™ technology platform which has progressed into clinical development. This achievement demonstrates the versatility and robustness of our LNAplus™ technology platform. We are proud to have supported Lipigon's success story and look forward to following their next advancements in developing a new, effective treatment option for patients suffering from rare lipid disorders." The Lipigon trial aims to document the safety pro Lipisense , as well as its pharmacokinetic properties and pharmacodynamic effects. Lipisense is a first-in-class therapeutic that addresses elevated levels of plasma lipid triglycerides in patients suffering from severe hypertriglyceridemia as well as the rare disease Familial Chylomicronemia Syndrome (FCS), diseases that may lead to the painful and potentially life-threatening syndrome, acute pancreatitis. The RNA-based drug candidate allows for the specific targeting of the disease-inducing protein while maintaining overall safety pro The molecule downregulates the cellular production of Angiopoietin like 4 ("ANGPTL4"), a protein that plays an important role in lipid metabolism, resulting in the reduction of lipids, specifically in the liver. Secarna has several successful pharma/biotech-partnered programs including multi-program collaborations with Evotec, Denali Therapeutics and Achilles. The Company also maintains a diversified in-house pipeline of 11 promising ASO programs with most advanced pre-clinical projects in the immune oncology and fibrotic/inflammatory disease spaces. About Secarna's proprietary drug discovery and development platform, LNAplus™ Secarna's proprietary, customized LNAplus™ platform is being applied to the discovery, testing and selection of antisense oligonucleotides (ASOs) for pre-clinical and clinical development. LNAplus™ encompasses all aspects of drug discovery and pre-clinical development and has proven to be fast, reliable, scalable and efficient, enabling the discovery of novel antisense-based therapies for challenging or currently undruggable targets.The platform includes the powerful proprietary Oligofyer™ bioinformatics pipeline, a streamlined, high efficiency screening process, including Secarna's proprietary LNA-Vit(r)ox™ safety test system, as well as target-specific functional assays. Secarna's platform and ASOs have been validated by numerous in-house projects as well as in several academic and industry collaborations. About Secarna Pharmaceuticals GmbH & Co. KG Secarna Pharmaceuticals is the leading independent European next-generation antisense drug discovery and development company addressing high unmet medical needs in immuno-oncology and immunology, as well as viral, neurodegenerative and cardiometabolic diseases. Secarna's mission is to maximize the performance and output of its proprietary LNAplus™ antisense oligonucleotide discovery platform, as well as to develop highly specific, safe, and efficacious best-in-class antisense therapies. With over 15 development programs, including both proprietary pipeline projects and partnered programs, Secarna focuses on targets in indications where antisense-based approaches have clear potential benefits over other therapeutic modalities. Contact Secarna Pharmaceuticals GmbH & Co. KG Alexander Gebauer, MD, PhD CEO alexander.gebauer@secarna.com Secarna Pharmaceuticals GmbH & Co. KG Am Klopferspitz 19 82152 Planegg/Martinsried Tel.: +49 89 215 46 375 For media enquiries Anne Hennecke/Brittney Sojeva MC Services AG secarna@mc-services.eu Tel.: +49 211 529252 14 SOURCE: Secarna Pharmaceuticals GmbH & Co. KG View source version on accesswire.com:
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.